Honig P K, Wortham D C, Zamani K, Conner D P, Mullin J C, Cantilena L R
Division of Clinical Pharmacology, Uniformed Services University of the Health Sciences, Bethesda, Md. 20814-4799.
JAMA. 1993;269(12):1513-8.
To examine prospectively the effects of ketoconazole on the pharmacokinetics and electrocardiographic repolarization pharmacodynamics (corrected QT intervals) of terfenadine in men and women.
Prospective cohort study with each subject serving as his or her own control.
Outpatient cardiology clinic and inpatient telemetry unit for monitoring period.
Six healthy volunteers (four men and two women, aged 24 to 35 years) not taking any prescription or over-the-counter medications.
After achieving a steady state while taking terfenadine (60 mg every 12 hours for 7 days), daily concomitant oral ketoconazole (200 mg every 12 hours) was added to the subjects' regimen. Pharmacokinetic profiles were obtained while subjects were taking terfenadine alone and after the addition of ketoconazole. Electrocardiograms were obtained at baseline, after 1 week of taking terfenadine alone, and at the time of the second pharmacokinetic profile after the addition of ketoconazole to the regimen.
Terfenadine and its acid metabolite serum concentrations and corrected QT intervals.
All subjects had detectable levels of unmetabolized terfenadine after the addition of ketoconazole, which was associated with QT prolongation. Only two of the six subjects could complete the entire course of ketoconazole coadministration. Four subjects received a shortened duration of ketoconazole therapy because of significant electrocardiographic repolarization abnormalities. There was a significant change in the area under the curve of the acid metabolite of terfenadine after the addition of ketoconazole administration.
Ketoconazole alters the metabolism of terfenadine in normal men and women and results in the accumulation of unmetabolized parent drug, which is associated with significant prolongation of the corrected QT interval. This drug combination should be avoided.
前瞻性研究酮康唑对特非那定在男性和女性体内药代动力学及心电图复极药效学(校正QT间期)的影响。
前瞻性队列研究,每位受试者作为自身对照。
门诊心脏病诊所及住院遥测病房用于监测期。
6名健康志愿者(4名男性和2名女性,年龄24至35岁),未服用任何处方药或非处方药。
在服用特非那定(每12小时60毫克,共7天)达到稳态后,每日加用口服酮康唑(每12小时200毫克)。在受试者单独服用特非那定期间及加用酮康唑后获取药代动力学曲线。在基线、单独服用特非那定1周后以及在治疗方案中加用酮康唑后的第二次药代动力学曲线测定时获取心电图。
特非那定及其酸性代谢产物血清浓度和校正QT间期。
加用酮康唑后,所有受试者均检测到未代谢的特非那定水平,这与QT间期延长有关。6名受试者中只有2名能够完成酮康唑联合给药的整个疗程。4名受试者因明显的心电图复极异常而缩短了酮康唑治疗疗程。加用酮康唑给药后,特非那定酸性代谢产物的曲线下面积有显著变化。
酮康唑改变了正常男性和女性体内特非那定的代谢,导致未代谢母体药物蓄积,这与校正QT间期显著延长有关。应避免这种药物组合。